摘要
目的:探讨联用阿立哌唑对改善抗精神病药物所致高催乳激素血症的疗效及安全性。方法对70例服用其它单一抗精神病药物治疗且剂量固定4周以上精神分裂症患者,根据随机数字表法分为治疗组35例,对照组35例。治疗组在服用原药的基础上,每天联用阿立哌唑2.5 mg,对照组维持以前的药物治疗。两组均在治疗前及治疗第4周末分别测定患者血清催乳激素水平,并进行比较。同时用阳性和阴性症状量表(PANSS)评定临床症状程度,不良副反应量表(TESS)评定不良反应情况。结果治疗组患者血清催乳激素水平明显下降[(78.64±30.15)μg/L与(35.01±13.99)μg/L,t=9.585,P<0.05],对照组血清催乳激素水平无明显变化[(80.34±46.08)μg/L与(79.94±43.84)μg/L,t=0.084,P>0.05]。两组PANSS、TESS评分差异均无统计学意义(均P>0.05)。结论联用阿立哌唑对抗精神病药物所致高催乳激素血症有一定的治疗作用,并且相对安全。
Objective To investigate the efficacy and safety of combined with aripiprazole to improve hyper-prolactinemia caused by antipsychotic drugs.Methods 70 patients with schizophrenia who had been treated with antipsychotic drugs for 4 weeks prior to the study were divided into the two groups by random number table method:the treatment group(35 cases)were given each additionally 2.5 mg of aripiprazole oral,one time every day.The con-trol group (35 cases)continued with no extra management.The treatment group on the basis of the original drug administered daily in combination with aripiprazole 2.5mg,the control group maintained the previous drug treatment. Serum prolactin concentrations were assayed in patients of both groups before treatment and after 4 weeks treatment. At the same time,used the positive and negative symptom scale (PANSS)to assess the state of the clinical symptoms. The side effects were evaluated by Treatment Emergent Symptom Scale(TESS).Results After combined with aripi-prazole,it demonstrated that serum prolactin level in patients of the treatment group were significantly lowered [(78.64 ±30.15)μg/L vs (35.01 ±13.99)μg/L,t=9.585,P〈0.05],while those in patients of the control group had no change[(80.34 ±46.08)μg/L vs (79.94 ±43.84)μg/L,t=0.084,P〉0.05].There were no significant differences between the two groups of PANSS and TESS scores(all P〉0.05 ).Conclusion Combined with aripi-prazole for antipsychotic-induced hyperprolactinemia have a therapeutic effect and relatively safe.
出处
《中国基层医药》
CAS
2015年第8期1187-1189,共3页
Chinese Journal of Primary Medicine and Pharmacy